FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283383180> ?p ?o ?g. }

• W4283383180 abstract "Abstract The success of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes (T2D) and obesity has sparked considerable efforts to develop next-generation co-agonists that are more effective. We conducted a randomised, placebo-controlled phase 1b study (ClinicalTrials.gov: NCT04466904) to evaluate the safety and efficacy of IBI362 (LY3305677), a GLP-1 and glucagon receptor dual agonist, in Chinese patients with T2D. A total of 43 patients with T2D were enrolled in three cohorts in nine study centres in China and randomised in each cohort to receive once-weekly IBI362 (3.0 mg, 4.5 mg or 6.0 mg), placebo or open-label dulaglutide (1.5 mg) subcutaneously for 12 weeks. Forty-two patients received the study treatment and were included in the analysis, with eight receiving IBI362, four receiving placebo and two receiving dulaglutide in each cohort. The patients, investigators and study site personnel involved in treating and assessing patients in each cohort were masked to IBI362 and placebo allocation. Primary outcomes were safety and tolerability of IBI362. Secondary outcomes included the change in glycated haemoglobin A 1c (HbA 1c ), fasting plasma glucose (FPG) and post-mixed-meal tolerance test (post-MTT) glucose levels. IBI362 was well tolerated. Most commonly-reported treatment-emergent adverse events were diarrhoea (29.2% for IBI362, 33.3% for dulaglutide, 0% for placebo), decreased appetite (25.0% for IBI362, 16.7% for dulaglutide, 0% for placebo) and nausea (16.7% for IBI362, 16.7% for dulaglutide and 8.3% for placebo). HbA 1c , FPG and post-MTT glucose levels were reduced from baseline to week 12 in patients receiving IBI362 in all three cohorts. IBI362 showed a favourable safety profile and clinically meaningful reductions in blood glucose in Chinese patients with T2D." @default.
• W4283383180 created "2022-06-25" @default.
• W4283383180 creator A5005946727 @default.
• W4283383180 creator A5018063525 @default.
• W4283383180 creator A5019598632 @default.
• W4283383180 creator A5027475930 @default.
• W4283383180 creator A5037239499 @default.
• W4283383180 creator A5038327368 @default.
• W4283383180 creator A5044609588 @default.
• W4283383180 creator A5054156681 @default.
• W4283383180 creator A5065863816 @default.
• W4283383180 creator A5070677531 @default.
• W4283383180 creator A5076554533 @default.
• W4283383180 creator A5086877102 @default.
• W4283383180 creator A5087592842 @default.
• W4283383180 date "2022-06-24" @default.
• W4283383180 modified "2023-10-14" @default.
• W4283383180 title "A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes" @default.
• W4283383180 cites W1773084519 @default.
• W4283383180 cites W1993582432 @default.
• W4283383180 cites W2148275037 @default.
• W4283383180 cites W2148623180 @default.
• W4283383180 cites W2574032118 @default.
• W4283383180 cites W2765417728 @default.
• W4283383180 cites W2791011305 @default.
• W4283383180 cites W2793160130 @default.
• W4283383180 cites W2802400646 @default.
• W4283383180 cites W2808958607 @default.
• W4283383180 cites W2808959426 @default.
• W4283383180 cites W2886911834 @default.
• W4283383180 cites W2982427683 @default.
• W4283383180 cites W3004650835 @default.
• W4283383180 cites W3013228862 @default.
• W4283383180 cites W3086646659 @default.
• W4283383180 cites W3087889571 @default.
• W4283383180 cites W3093123473 @default.
• W4283383180 cites W3121704649 @default.
• W4283383180 cites W3123792142 @default.
• W4283383180 cites W3159068931 @default.
• W4283383180 cites W3159925822 @default.
• W4283383180 cites W3175013534 @default.
• W4283383180 cites W3176152733 @default.
• W4283383180 cites W3176758271 @default.
• W4283383180 cites W3194756735 @default.
• W4283383180 cites W3195404919 @default.
• W4283383180 cites W4211058450 @default.
• W4283383180 cites W814962454 @default.
• W4283383180 doi "https://doi.org/10.1038/s41467-022-31328-x" @default.
• W4283383180 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35750681" @default.
• W4283383180 hasPublicationYear "2022" @default.
• W4283383180 type Work @default.
• W4283383180 citedByCount "10" @default.
• W4283383180 countsByYear W42833831802022 @default.
• W4283383180 countsByYear W42833831802023 @default.
• W4283383180 crossrefType "journal-article" @default.
• W4283383180 hasAuthorship W4283383180A5005946727 @default.
• W4283383180 hasAuthorship W4283383180A5018063525 @default.
• W4283383180 hasAuthorship W4283383180A5019598632 @default.
• W4283383180 hasAuthorship W4283383180A5027475930 @default.
• W4283383180 hasAuthorship W4283383180A5037239499 @default.
• W4283383180 hasAuthorship W4283383180A5038327368 @default.
• W4283383180 hasAuthorship W4283383180A5044609588 @default.
• W4283383180 hasAuthorship W4283383180A5054156681 @default.
• W4283383180 hasAuthorship W4283383180A5065863816 @default.
• W4283383180 hasAuthorship W4283383180A5070677531 @default.
• W4283383180 hasAuthorship W4283383180A5076554533 @default.
• W4283383180 hasAuthorship W4283383180A5086877102 @default.
• W4283383180 hasAuthorship W4283383180A5087592842 @default.
• W4283383180 hasBestOaLocation W42833831801 @default.
• W4283383180 hasConcept C126322002 @default.
• W4283383180 hasConcept C134018914 @default.
• W4283383180 hasConcept C142724271 @default.
• W4283383180 hasConcept C170493617 @default.
• W4283383180 hasConcept C185280430 @default.
• W4283383180 hasConcept C197934379 @default.
• W4283383180 hasConcept C204787440 @default.
• W4283383180 hasConcept C27081682 @default.
• W4283383180 hasConcept C2777180221 @default.
• W4283383180 hasConcept C2778375690 @default.
• W4283383180 hasConcept C2778938600 @default.
• W4283383180 hasConcept C2779829264 @default.
• W4283383180 hasConcept C2780533449 @default.
• W4283383180 hasConcept C2780580376 @default.
• W4283383180 hasConcept C555293320 @default.
• W4283383180 hasConcept C71924100 @default.
• W4283383180 hasConcept C98274493 @default.
• W4283383180 hasConceptScore W4283383180C126322002 @default.
• W4283383180 hasConceptScore W4283383180C134018914 @default.
• W4283383180 hasConceptScore W4283383180C142724271 @default.
• W4283383180 hasConceptScore W4283383180C170493617 @default.
• W4283383180 hasConceptScore W4283383180C185280430 @default.
• W4283383180 hasConceptScore W4283383180C197934379 @default.
• W4283383180 hasConceptScore W4283383180C204787440 @default.
• W4283383180 hasConceptScore W4283383180C27081682 @default.
• W4283383180 hasConceptScore W4283383180C2777180221 @default.
• W4283383180 hasConceptScore W4283383180C2778375690 @default.
• W4283383180 hasConceptScore W4283383180C2778938600 @default.
• W4283383180 hasConceptScore W4283383180C2779829264 @default.
• W4283383180 hasConceptScore W4283383180C2780533449 @default.
• W4283383180 hasConceptScore W4283383180C2780580376 @default.

• next